ReviewDrugs2015
Droxidopa: a review of its use in symptomatic neurogenic orthostatic hypotension.
Review in Drugs, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03602014 (Dose Response to the Norepinephrine Precursor Droxidopa in Hypotensive Individuals With Spinal Cord Injury), which is not on this map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Dose Response to the Norepinephrine Precursor Droxidopa in Hypotensive Individuals With Spinal Cord Injury
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 51 citations in OpenAlex.
- Management of Hypertension and Blood Pressure Dysregulation in Patients with Parkinson's Disease-a Systematic Review.Current hypertension reports · 2021Pooled it
- Prevalence, risk factors, and prognosis of orthostatic hypotension in diabetic patients: A systematic review and meta-analysis.Medicine · 2017Pooled it
- Article
- Review
- Use of droxidopa for blood pressure augmentation after acute spinal cord injury: case reports.Acute and critical care · 2025Article
- Ampreloxetine Versus Droxidopa in Neurogenic Orthostatic Hypotension: A Comparative Review.Cureus · 2023Review
- Epilepsy and Attention Deficit Hyperactivity Disorder: Connection, Chance, and Challenges.International journal of molecular sciences · 2023Review
- Treatment strategies for clozapine-induced hypotension: a systematic review.Therapeutic advances in psychopharmacology · 2022Review
- Drug-Related Orthostatic Hypotension: Beyond Anti-Hypertensive Medications.Drugs & aging · 2020Review
- Neurogenic Orthostatic Hypotension: State of the Art and Therapeutic Strategies.Clinical Medicine Insights. Cardiology · 2020Review
- Management of the "notorious" refractory orthostatic hypotension: Let's think and further study droxidopa.Journal of clinical hypertension (Greenwich, Conn.) · 2019Article
- Autonomic Dysfunction: How to Identify and When to Treat?High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2016Review
- Pathophysiology and Treatment of Orthostatic Hypotension in Parkinsonian Disorders.Current treatment options in neurology · 2016Review
- Acute orthostatic responses during early mobilisation of patients with acquired brain injury - Innowalk pro versus standing frame.Journal of rehabilitation and assistive technologies engineeringArticle
- Pure Autonomic Failure with Asymptomatic Hypertensive Urgency: A Case Report and Literature Review.Case reports in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The norepinephrine prodrug droxidopa (NORTHERA™) is approved in the US for the treatment of orthostatic dizziness, lightheadedness, or the 'feeling that you are about to black out' in adults with symptomatic neurogenic orthostatic hypotension associated with primary autonomic failure (e.g. Parkinson's disease, multiple system atrophy or pure autonomic failure), dopamine β-hydroxylase deficiency or nondiabetic autonomic neuropathy. This article reviews the clinical efficacy and tolerability of droxidopa in symptomatic neurogenic orthostatic hypotension, as well as summarizing its pharmacological properties. Oral droxidopa was effective in the shorter-term treatment of patients with symptomatic neurogenic orthostatic hypotension, with improvements seen in symptoms, the impact of symptoms on daily activities and standing systolic blood pressure. More data are needed to confirm the longer-term efficacy of droxidopa. Droxidopa was generally well tolerated, although patients should be monitored for supine hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.